Yas Marina Circuit and Porsche Centre Abu Dhabi, Ali & Sons, Extend Strategic Partnership – Featuring the Latest Porsche Taycan Turbo and Expanded Driving Experiences
Yas Marina Circuit and Porsche Centre Abu Dhabi, Ali & Sons Co. LLC, have officially announced the extension of their long-standing partnership, reinforcing their shared commitment to delivering world-class automotive experiences in the capital.
The renewed collaboration continues to merge Porsche's performance legacy with Yas Marina Circuit's state-of-the-art facilities, offering exclusive customer activations, bespoke track day events, and premium access to the circuit's iconic motorsport calendar – including the Formula 1® Etihad Airways Abu Dhabi Grand Prix.
As part of the partnership, the latest-generation Porsche Taycan Turbo has joined the DriveYAS fleet, offering guests a premium electric driving experience that combines thrilling acceleration, advanced handling, and sustainable performance.
Ali Al Beshr, General Manager of Yas Marina Circuit, commented:
'Our partnership with Porsche Centre Abu Dhabi is rooted in a shared pursuit of excellence. The addition of the new Taycan Turbo to our DriveYAS fleet reaffirms our commitment to bringing the latest innovations in performance driving to the heart of Abu Dhabi. Together, we are creating unforgettable experiences for fans, drivers, and automotive enthusiasts alike.'
Wissam Khalil, General Manager of Porsche Centre Abu Dhabi, added:
'Extending our partnership with Yas Marina Circuit allows us to continuously engage with our customers in unique and meaningful ways. From dynamic track days to electrifying DriveYAS sessions, and the incredible backdrop of Formula 1 weekend, this collaboration showcases the full potential of Porsche's performance in a setting that's as extraordinary as our vehicles.'
The Porsche Taycan Turbo is a technological marvel – boasting up to 680 PS (671 hp) with overboost power, lightning-fast 0 to 00 km/h acceleration in just 3.2 seconds, and Porsche Active Suspension Management for exceptional track handling. With its all-electric drivetrain, the Taycan Turbo delivers powerful, sustainable performance without compromise – making it the ideal fit for Yas Marina Circuit's forward-looking driving experiences.
In addition to its presence on the DriveYAS lineup, Porsche Centre Abu Dhabi will continue to activate during major motorsport events, including exclusive displays and VIP experiences during Formula 1 weekend, while also hosting tailored track day events for Porsche owners and prospects throughout the year.
This extended partnership represents a dynamic blend of innovation, heritage, and high-performance culture – bringing together two brands that share a passion for driving excellence.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TECHx
11 hours ago
- TECHx
AmiViz Ranked Among Top Tech Workplaces in GCC
Home » Tech Value Chain » Distributors » AmiViz Ranked Among Top Tech Workplaces in GCC AmiViz, a cybersecurity-focused value-added distributor based in the Middle East, has been ranked 22nd on the 2025 list of Best Workplaces in Technology in the GCC region. The ranking was announced by Great Place to Work®, a global authority on workplace culture. This recognition highlights AmiViz's strong commitment to creating an inclusive, empowering, and innovation-driven work environment. It reflects the company's efforts to foster a culture where trust, collaboration, and professional growth are a priority. According to Great Place to Work®, the ranking is based on employee feedback collected through confidential surveys. It also includes an in-depth assessment of the company's HR practices, leadership involvement, and focus on employee well-being. AmiViz stood out for promoting a transparent and agile workplace. The company was recognized for encouraging employees to excel and contribute meaningfully to its mission. The company reported that its people-centric approach remains a core value. It continues to invest in employee development and well-being while navigating a rapidly evolving tech landscape. AmiViz promotes continuous learning and upskilling The company values diversity and encourages innovation Ilyas Mohammed, Chief Operating Officer at AmiViz, expressed pride in the achievement. He stated, 'Being recognized among the top workplaces in technology across the GCC is an honour that validates our belief that a strong company culture is a catalyst for sustainable growth. Our team is at the heart of everything we do, and this recognition is a reflection of their passion, dedication, and the values we live by every day.' The company revealed that this recognition comes during a phase of strategic expansion. It also highlights AmiViz's ability to scale while maintaining its core values. AmiViz continues to strengthen its position in cybersecurity distribution across the region. The company emphasized that its workplace culture plays a key role in this success. This announcement sends a clear message to employees, partners, and stakeholders. AmiViz is not only a leader in cybersecurity solutions but also a company that values its people as its greatest asset.
Arabian Post
14 hours ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
Dubai Eye
a day ago
- Dubai Eye
F1 replaces Imola with Madrid on 2026 calendar
The 24-race Formula 1 slate for 2026 features a grand prix in Madrid replacing Italy's Emilia Romagna GP at Imola. Governing body FIA approved the calendar on Tuesday during a meeting of the World Motor Sport Council. The final race on Imola's current contract was last month, won by four-time reigning world champion Max Verstappen. The 2026 race in Madrid, first announced in 2024, is scheduled for September 13. The season opens in Melbourne, Australia, on March 8 and runs through December 6 at Abu Dhabi in the UAE. Three races remain on the US calendar: Miami (May 3), Austin - Texas (Oct. 25) and Las Vegas (November 21). The 2026 F1 event schedule: March 6-8, Australian Grand Prix, Melbourne March 13-15, Chinese Grand Prix, Shanghai March 27-29, Japanese Grand Prix, Suzuka April 10-12, Bahrain Grand Prix, Sakhir April 17-19, Saudi Arabian Grand Prix, Jeddah May 1-3, Miami Grand Prix, Miami Gardens May 22-24, Canadian Grand Prix, Montreal June 5-7, Monaco Grand Prix, Monaco June 12-14, Spanish Grand Prix, Barcelona June 26-28, Austrian Grand Prix, Spielberg July 3-5, British Grand Prix, Silverstone July 17-19, Belgian Grand Prix, Spa-Francorchamps July 24-26, Hungarian Grand Prix, Budapest Aug. 21-23, Dutch Grand Prix, Zandvoort Sept. 4-6, Italian Grand Prix, Monza Sept. 11-13, Madrid Grand Prix, Madrid Sept. 25-27, Azerbaijan Grand Prix, Baku Oct. 9-11, Singapore Grand Prix, Singapore Oct. 23-25, U.S. Grand Prix, Austin Oct. 30-Nov. 1, Mexico Grand Prix, Mexico City Nov. 6-8, Brazilian Grand Prix, Sao Paulo Nov. 19-21, Las Vegas Grand Prix, Las Vegas Nov. 27-29, Qatar Grand Prix, Lusail Dec. 4-6, Abu Dhabi Grand Prix, Yas Marina Save the date 🔒 Presenting the 2026 Calendar 🗓️ 24 races across the world to crown our champion 🏆 #F1 #Formula1 — Formula 1 (@F1) June 10, 2025
